Real-world PD-L1 testing, fi rst-line therapy for advanced NSCLC, and fi rst-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC in the Czech Republic
- PMID: 40762199
- DOI: 10.48095/ccko2025192
Real-world PD-L1 testing, fi rst-line therapy for advanced NSCLC, and fi rst-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC in the Czech Republic
Abstract
Background: This study aimed to describe real-world PD-L1 testing and first-line (1L) treatment patterns for advanced non-small cell lung cancer (NSCLC), and clinical outcomes for metastatic NSCLC after 1L pembrolizumab monotherapy became reimbursed in the Czech Republic (February 2019).
Patients and methods: This descriptive noninterventional study drew on two Czech lung cancer registries. We examined PD-L1 testing patterns and results in the KELLY registry for samples submitted on/after 1-Feb-2019 from adult patients with advanced NSCLC. Using the TULUNG registry, we summarized 1L targeted therapies initiated on/after 1-Feb-2019 for advanced NSCLC, in addition to characteristics and outcomes for patients treated with 1L pembrolizumab monotherapy for metastatic NSCLC, PD-L1 tumor proportion score (TPS) ≥ 50%, and no known EGFR/ALK alterations. Real-world time on treatment (rwToT) and overall survival (OS) were determined using Kaplan-Meier curves. The data cutoff was 16-Sept-2021.
Results: The percentage of NSCLC samples in the KELLY registry tested for PD-L1 expression increased from 70.5% in 2019 to 84.4% in 2021. Pembrolizumab monotherapy was the most common 1L targeted therapy in 2019-2021 for patients with advanced NSCLC and PD-L1 TPS ≥ 50% (N = 315), administered to 70-80% each year. Of 235 patients with metastatic NSCLC who received 1L pembrolizumab monotherapy, median age was 69 years, 54% were men, 52% were current smokers, and 28% had squamous NSCLC. Median rwToT was 8.5 months (95% CI; 6.7-10.1), with 6- and 12-month on-treatment rates of 59% and 36%, respectively, for 199 patients with ≥ 6 months of follow-up. With added national registry mortality data, estimated median OS was 13.7 months (12.3-17.7); 6- and 12-month OS rates were 70% and 59%, respectively.
Conclusions: The rates of PD-L1 testing increased from 2019 to 2021. Median OS among patients with metastatic NSCLC and PD-L1 TPS ≥ 50% treated with pembrolizumab was lower than in clinical trials, likely due to differences between real-world patients and trial participants in age, smoking status, performance status, and squamous histology.
Keywords: Czech Republic; carcinoma; immunotherapy; immunotherapy; lung cancer; non-small-cell lung; pembrolizumab monotherapy; programmed death-ligand 1; real-world data.
Similar articles
-
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.J Cancer Res Clin Oncol. 2021 Aug;147(8):2459-2469. doi: 10.1007/s00432-021-03527-4. Epub 2021 Feb 1. J Cancer Res Clin Oncol. 2021. PMID: 33523301 Free PMC article.
-
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30. Lung Cancer. 2019. PMID: 31319971
-
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.J Cancer Res Clin Oncol. 2020 Feb;146(2):457-466. doi: 10.1007/s00432-019-03072-1. Epub 2019 Dec 18. J Cancer Res Clin Oncol. 2020. PMID: 31853661 Free PMC article.
-
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.Clin Transl Oncol. 2024 Oct;26(10):2488-2502. doi: 10.1007/s12094-024-03442-3. Epub 2024 Apr 16. Clin Transl Oncol. 2024. PMID: 38625495
-
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.J Thorac Oncol. 2025 Jul;20(7):941-954. doi: 10.1016/j.jtho.2025.03.033. Epub 2025 Mar 19. J Thorac Oncol. 2025. PMID: 40118215 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous